Join
Live feed
·
PRReleasevia Quantisnow
NeuroBo Pharmaceuticals Inc. logo

NeuroBo Pharmaceuticals Announces Positive Top-Line Data From the SAD Part 1 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

ByQuantisnow·Wall Street's wire, on your screen.
NRBO· NeuroBo Pharmaceuticals Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track NRBO (NeuroBo Pharmaceuticals Inc.) and more on Quantisnow.